Mind Medicine (MindMed) Inc. (MNMD) closed the last trading session at $6.45, gaining 16.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $24.50 indicates a 279.8% upside potential.The average comprises 10 short-term price targets ranging from a low of $16 to a high of $55, with a standard deviation of $12.13. While the lowest estimate indicates an increase of 148.1% from the cur ...

Corporate Presentation May 2025 Disclaimer Cautionary Note Regarding Forward-Looking Statements This Presentation contains, and our officers and representatives may from time to time make, "forward-looking statements" within the meaning of applicable securities laws and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual res ...

Mind Medicine (MindMed) (MNMD) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Good morning and welcome to the MindMed's First Quarter twenty twenty five Financial Results and Corporate Update Webcast. Currently, all participants are in a listen only mode. This webcast is live on the Investors and Media section of MindMed's website at mindmed.co, and a replay will be available after the webcast. I would like to introduce Stephanie Fagan, Chief Corporate Affairs Officer of Please go ahead. Speaker1 T ...

Mind Medicine (MindMed) (MNMD) Q4 2024 Earnings Call March 06, 2025 05:13 PM ET Company Participants Stephanie Fagan - Chief Corporate Affairs OfficerRobert Barrow - Director & CEODaniel Karlin - Chief Medical OfficerMadhu Yennawar - Vice PresidentGavin Clark-Gartner - Director - Biotechnology Equity ResearchSumant Kulkarni - Managing DirectorPatrick Trucchio - Managing Director Conference Call Participants None - AnalystCharles Duncan - AnalystJoel Beatty - Senior Research AnalystRudy Li - Senior Research ...

Core Viewpoint - Mind Medicine's stock has experienced significant gains following the confirmation of Robert F. Kennedy Jr. as the new HHS secretary, which is expected to positively impact the company's market position due to Kennedy's support for psychedelic treatments [1][2][3]. Company Developments - Mind Medicine's share price increased by 16.9% as of 3:15 p.m. ET, with a peak increase of 20.7% earlier in the session [1]. - The company has not yet recorded any revenue but is advancing in its clinical testing phases for its core treatments [4]. Regulatory Environment - Robert F. Kennedy Jr. was confirmed as HHS secretary with a 52-to-48 Senate vote, receiving nearly unanimous support from Republicans, except for one dissenting vote [2]. - Kennedy's previous advocacy for psychedelic drugs as therapeutic options may facilitate Mind Medicine's efforts to bring its products to market [3]. Clinical Trials - Mind Medicine announced a phase 3 study for lysergide D-tartrate (LSD) targeting generalized anxiety disorder, set to begin in the first half of 2025 [5]. - The company has dosed the first patient in the clinical trial, which is expected to involve approximately 250 patients, with results likely to significantly influence the company's share price [5].

Mind Medicine (MNMD 9.04%) stock is posting big gains in Tuesday's trading. The biotech company's share price was up 8.7% as of 2 p.m. ET despite a 0.8% pullback for the S&P 500 index and a 1.5% decline for the Nasdaq Composite index.MindMed stock is surging today following a recent report from a Minnesota-based task force that urged the decriminalization of psychedelic mushrooms. The clinical-stage biotech specialist is focused on potential medical applications for psychedelics, and it stands to benefit if ...

Mind Medicine (MindMed) (MNMD) is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate (LSD), for the treatment of generalized anxiety disorder (GAD) and major depressive disorder (MDD).2024 Turns Out to Be a Transformational Year for MindMed2024 was a transformational year for the company when it executed many important milestones, one of which was initiating the 52-week Voyage phase III study on MM120 ODT in GAD ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This writing is for informational purposes only. All opinions expressed herein are not investment rec ...

Financial Data and Key Metrics Changes - As of September 30, 2024, the company reported cash and cash equivalents of $295.3 million, a significant increase from $99.7 million as of December 31, 2023, indicating a strong cash runway into 2027 [34] - The net loss for the quarter was $13.7 million, down from $17.9 million in the same period in 2023, reflecting a decrease of $4.2 million primarily due to changes in the fair value of warrants [37] Business Line Data and Key Metrics Changes - Research and development expenses increased to $17.2 million for the quarter, up from $13.2 million in the same period last year, driven by advancements in pivotal studies for MM120 ODT [35] - General and administrative expenses decreased to $7.6 million from $8.4 million year-over-year, attributed to lower legal and commercial spending [36] Market Data and Key Metrics Changes - The company is focused on addressing significant unmet medical needs in generalized anxiety disorder (GAD) and major depressive disorder (MDD), which together affect approximately 51 million adults in the U.S. [10] Company Strategy and Development Direction - The company is on track to initiate its first Phase 3 study of MM120 ODT in GAD by the end of 2024 and plans to start the second Phase 3 study in GAD and the first in MDD in the first half of 2025 [9][29] - The development strategy emphasizes clean study designs and operational efficiency, aiming to replicate the rapid and durable response observed in Phase 2b studies [14][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of MM120 ODT to transform treatment for GAD and MDD, highlighting the enthusiasm from patients and stakeholders [11][20] - The company anticipates that successful completion of the Phase 3 studies will drive significant value and is focused on maintaining a strong execution track record [38] Other Important Information - The company aims to address functional unblinding issues in clinical trials by implementing strategies such as using central raters and incorporating questionnaires to assess expectancy bias [16][44] - The Phase 3 studies will include adaptive designs with interim analyses to ensure statistical power and interpretability of results [24][67] Q&A Session Summary Question: How do you think having fewer arms in the Phase 3 program could impact central rater unblinding? - Management indicated that data from Phase 2 will be crucial for the submission, showing that functional unblinding did not impact study outcomes significantly [42] Question: Do you foresee having any particular difficulties in initiating Voyage and Panorama in GAD? - Management expressed confidence in their clinical development team's ability to operationalize protocols effectively, expecting to maintain enrollment success similar to Phase 2 [48] Question: What would you anticipate for enrollment pacing in the Voyage study? - Management expects to execute the study efficiently, with top-line readouts anticipated in the first half of 2026 [55] Question: Will the interim analysis trigger an early stoppage? - Management clarified that the interim analysis will not involve testing for futility or early efficacy but will ensure that nuisance parameters are consistent with initial assumptions [67] Question: What are you looking to learn from additional regulatory discussions regarding the second potential Phase 3 trial? - Management aims to ensure alignment from a programmatic standpoint across indications, especially for MDD [74] Question: How will you maintain the integrity of the durability of effect in the open-label extension program? - Management stated that the same restrictions on concomitant medications will apply during the extension phase to maintain integrity [86]

Corporate Presentation November 2024 Disclaimer This presentation (the "Presentation") has been prepared by Mind Medicine (MindMed) Inc. ("MindMed", the "Company", "we", "our" or "us) solely for informational purposes. This Presentation does not constitute an offering of, or a solicitation of an offer to purchase, securities of MindMed and under no circumstances is it to be construed as a prospectus or advertisement or public offering of securities. Any trademarks included herein are the property of the own ...